Using Sacituzumab Govitecan and Other ADCs in Urothelial Cancers

March 6, 2019
Arlene O. Siefker-Radtke, MD

Arlene O. Siefker-Radtke, MD, discusses the data seen with sacituzumab govitecan, an antibody-drug conjugate that targets TROP-2, which is expressed frequently in urothelial cancer cells.

Arlene O. Siefker-Radtke, MD, professor, department of genitourinary medical oncology, division of cancer medicine, The University of Texas MD Anderson Cancer Center, discusses the data seen with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) that targets TROP-2, which is expressed frequently in urothelial cancer cells.

Response rates were around 30% with this agent, but it was associated with toxicites, says Siefker-Radtke. However, toxicities are common with other ADCs, such as enfortumab vedotin, which has a higher rate of neutropenia and neutropenic fevers.